Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
September 08, 2021 09:12 ET | Royal Biologics
HACKENSACK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP...
Royal Biologics Announces the Launch of Cryo-Cord™, the First Non-DMSO Viable Umbilical Cord Graft
January 21, 2020 11:13 ET | Royal Biologics
HACKENSACK, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company specializing in the research and advancement of novel ortho-biologics solutions, today announced the...
royallogo.png
Royal Biologics Launches MAGNUS, a DMSO-free Viable Cellular Bone Allograft
January 09, 2020 09:00 ET | Royal Biologics
HACKENSACK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Royal Biologics, an orthobiologics company specializing in the research and advancement of regenerative cellular therapy and novel orthobiologic...